Results 21 to 30 of about 30,028 (235)

Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link? [PDF]

International Journal of Cardiology. Hypertension, 2021
Dyslipidemia is known as a strong risk factor for premature atherosclerotic cardiovascular disease and increased morbidity and mortality and can have an adverse effect on left ventricular function due to direct or indirect macrovascular and/or ...
Antonio Vitarelli
doaj   +2 more sources

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia [PDF]

JACC: Basic to Translational Science
Summary: We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies to restore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH) and to enhance the macrophage-specific ...
Carla Borràs, MSc, Marina Canyelles, PhD, Josefa Girona, PhD, Daiana Ibarretxe, MD, PhD, David Santos, BS, Giovanna Revilla, PhD, Vicenta Llorente-Cortes, PhD, Noemí Rotllan, PhD, Petri T. Kovanen, MD, PhD, Matti Jauhiainen, PhD, Miriam Lee-Rueckert, PhD, Luis Masana, MD, PhD, Francisco Arrieta, MD, PhD, Javier Martínez-Botas, PhD, Diego Gómez-Coronado, PhD, Josep Ribalta, PhD, Mireia Tondo, PhD, Francisco Blanco-Vaca, MD, PhD, Joan Carles Escolà-Gil, PhD   +18 more
doaj   +2 more sources

High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.

Atherosclerosis, 2018
BACKGROUND AND AIMS Cardiovascular risk is high in heterozygous familial hypercholesterolemia (HeFH). The objective of this study was to describe recurrent cardiovascular events in selected patients with HeFH attending lipid clinics in France.
S. Béliard, F. Boccara, B. Cariou, A. Carrié, X. Collet, M. Farnier, J. Ferrières, M. Krempf, N. Peretti, J. Rabès, M. Varret, A. Vimont, S. Charrière, E. Bruckert, D. Angoulvant, S. Béliard, P. Benlian, C. Boileau, F. Boccara, E. Bruckert, B. Cariou, V. Carreau, A. Carrié, S. Charrière, M. Di Filippo, P. Ducluzeau, S. Dulong, V. Durlach, M. Farnier, E. Ferrari, J. Ferrières, A. Gallo, J. Girardet, R. Hankard, M. Krempf, J. Lalau, B. Lefort, J. Lemale, P. Moulin, F. Paillard, N. Peretti, A. Pradignac, Y. Pucheu, J. Rabès, S. Saheb, A. Sultan, P. Tounian, R. Valéro, M. Varret, B. Vergès, C. Yelnik, O. Ziegler   +51 more
semanticscholar   +3 more sources

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

PLoS ONE, 2016
The role of plasma cholesterol in impairing arterial function and elasticity remains unclear. We evaluated arterial stiffness, measured locally in the common carotid artery by high-resolution echo-tracking, and aortic stiffness, using carotid-femoral ...
Alexandra I Ershova, Alexey N Meshkov, Tatyana A Rozhkova, Maria V Kalinina, Alexander D Deev, Anatoliy N Rogoza, Tatyana V Balakhonova, Sergey A Boytsov   +7 more
doaj   +4 more sources

Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study

Journal of Lipid Research, 1999
Heterozygous familial hypercholesterolemia (FH) is associated with a moderate decrease of plasma apoA-I and HDL-cholesterol levels. The aim of the study was to test the hypothesis that these abnormalities were related to an increase of HDL-apoA-I ...
R Frénais, K Ouguerram, C Maugeais
exaly   +3 more sources

The genetics of familial hypercholesterolemia and emerging therapies

The Application of Clinical Genetics, 2015
Anja Vogt Medizinische Klinik und Poliklinik IV, Klinikum der Unversität München, Munich, Germany Abstract: Familial hypercholesterolemia (FH) results in very high levels of atherogenic low-density lipoprotein (LDL) cholesterol from the time ...
Vogt A
doaj   +1 more source

Aortic stiffness in young patients with heterozygous familial hypercholesterolemia

American Heart Journal, 1998
Dyslipidemia is a primary risk factor for the development of atherosclerosis. Aortic distensibility is an important determinant of left ventricular function and coronary blood flow whose possible alterations in patients with dyslipidemia have not been fully investigated.To assess the effect of dyslipidemia on the elastic properties of the aorta, we ...
Pitsavos, C, Toutouzas, K, Dernellis, J, Skoumas, J, Skoumbourdis, E, Stefanadis, C, Toutouzas, P   +6 more
openaire   +4 more sources

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia? [PDF]

Journal of Atherosclerosis and Thrombosis, 2022
Yu Kataoka, Sayaka Funabashi, Mariko Harada-Shiba   +2 more
exaly   +2 more sources

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
ABSTRACT Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, effectively reduce LDL‐C levels, improve cardiovascular outcomes, and are well tolerated in the treatment of heterozygous familial hypercholesterolemia (HeFH).
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +2 more sources

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). [PDF]

Front Cardiovasc Med, 2022
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and ...
Sudano I, Mach F, Moccetti T, Burkard T, Fahe C, Delabays A, Rickli H, Keller PF, Dopheide J, Bodenmann S, Fiolka T, Ehret G, Spirk D.   +12 more
europepmc   +2 more sources